Israel-based aesthetic device company Syneron Candela has secured the US Food and Drug Administration (FDA) approval for its PicoWay picosecond laser for coloured tattoo removal.

PicoWay uses a titanium sapphire laser to emit an ultra-short 785nm wavelength to remove blue and green coloured tattoos.

The ultra-short pulses of energy result in shorter and more comfortable treatments for patients while using the industry's shortest pulses and highest peak power.

The PicoWay's third wavelength completes the PicoWay laser platform which will contribute to a comprehensive removal and treatment of all colours of tattoos and pigmented lesions.

The FDA approval follows a study which involved 15 patients with 22 tattoos, 18 of which were coloured in blue and green.

A blinded assessment of the tattoo clearance by independent board-certified physicians has validated good to complete treatment response of 83% of the treated coloured tattoos.

The PicoWay treatments had also reported zero to negligible discomfort during the treatement.

Main Line Centre for Laser Surgery in suburban Philadelphia director, Candela Laser Corporation Medical Advisory Board chairman and FDA clinical study principal investigator Eric Bernstein said: "This is the first, ever, 785nm wavelength picosecond-domain laser in the world.

"This is the first, ever, 785nm wavelength picosecond-domain laser in the world."

“This novel addition to the PicoWay enables optimal treatment for blue and green tattoos, and is a welcome addition to the 532nm and 1,064nm wavelengths already available with the PicoWay.

“I am extremely impressed with Jay Bhawalkar and his engineering team at Candela, who developed the PicoWay.”

The new PicoWay picosecond laser is expected to be made available to US customers at the end of this year.

Image: Blue and green tattoo before and after being treated with new picosecond laser. Photo: courtesy of PRNewsFoto / Syneron Medical Ltd.